Outcome of Glargine Insulin in Renal Impairment Patients With Diabetic Ketoacidosis

• Status: Recruiting
• Trial end date: 2022-03-03
• Target enrollment: 0
• Participant gender: All

Summary

The study aims to compare between the use of continuous low dose insulin infusion versus co-administration of low dose continuous insulin infusion and early subcutaneous insulin glargine in diabetic ketoacidosis patients with chronic renal impairment. aim to investigate the effect of using the long acting insulin analogue glargine on the resolution time of diabetic ketoacidosis in renal impairment patients who have altered insulin pharmacokinetics and pharmacodynamics and the rate of adverse effects of this approach

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ain Shams University
• Treatments: Insulin Glargine

Criteria

Inclusion Criteria:

• Male and female patients.

• Type I and type II diabetes mellitus.

• Patients on insulin and/or oral hypoglycemic therapy.

• Duration of diabetes more than 5 years.

• Medical and surgical patients.

Exclusion Criteria:

• Severe persistent hypotension (SBP <80 inspite of receiving 1000ml of normal saline).

• Acute myocardial infarction.

• Progressive renal failure or end stage renal disease defined as eGFR < 15ml/min.

• Liver cell failure.

• Pregnancy.

• Need for emergency surgery